Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-08
2010-06-22
Chung, Susannah (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S389000, C548S250000
Reexamination Certificate
active
07741354
ABSTRACT:
The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy,wherein:R1represents heteroaryl, -carbocyclyl-heteroaryl, -alkenylheteroaryl or -alkylheteroaryl;R2represents alkyl, which may optionally be substituted by one or more groups selected from amino, halogen, hydroxyl, -alkoxy, -thioalkyl, —C(O)O-alkyl and —C(O)OH; carbocyclyl, which may optionally be substituted by one or more groups selected from alkyl, haloalkyl, amino, halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)O-alkyl and —C(O)OH; alkenyl; alkynyl; -alkyl-aryl; -alkyl-heteroaryl; -alkyl-heterocyclyl; -alkyl-carbocyclyl; -aryl-heteroaryl; -heteroaryl-aryl; -heteroaryl-heteroaryl; -aryl-aryl; -aryl (monocyclic or bicyclic); heteroaryl (monocyclic or bicyclic); heterocyclyl; or R2together with R4may form a carbocyclyl group optionally substituted by one or more alkyl groups;R3represents alkyl, which may optionally be substituted by one or more groups selected from amino, halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)OH and —C(O)O-alkyl; carbocyclyl, which may optionally be substituted by one or more groups selected from alkyl, amino, halogen, haloalkyl, hydroxyl, -alkoxy, -thioalkyl, —C(O)OH and —C(O)O-alkyl; alkenyl; -alkyl-aryl; -alkyl(aryl)2, -alkyl(heteroaryl)2, -alkyl(aryl)(heteroaryl), -alkyl-heteroaryl; -alkyl-heterocyclyl which heterocyclyl group may optionally be substituted by one or more groups selected from alkyl, hydroxy and oxo ; -alkyl-carbocyclyl; -aryl-heteroaryl; -heteroaryl-aryl; -aryl-aryl; -aryl-O-aryl, -heteroaryl-heteroaryl; -aryl; heteroaryl; heterocyclyl; -aryl-alkyl-aryl; -aryl-O-alkyl-aryl; -alkyl-C(O)—NH-alkyl-aryl; -alkyl-C(O)—NH-alkyl-heteroaryl; -alkyl-C(O)—NH-alkyl-heterocyclyl; -alkyl-C(O)—(N-piperidinyl) or -alkyl-C(O)—(N-pyrrolidinyl) in which piperidinyl or pyrrolidinyl may optionally be fused to optionally substituted phenyl.R4represents H or alkyl.
REFERENCES:
patent: 5721234 (1998-02-01), Bigge et al.
patent: 7304086 (2007-12-01), Schilling
patent: 7371871 (2008-05-01), Schilling
patent: 7381537 (2008-06-01), Demuth
patent: 7462599 (2008-12-01), Schilling
patent: 2005/0137142 (2005-06-01), Schultz
patent: 2005/0171112 (2005-08-01), Schultz
patent: 2006/0100253 (2006-05-01), Niestroj
patent: 2007/0191366 (2007-08-01), Hoffmann
patent: 2008/0153892 (2008-06-01), Schilling
patent: 2008/0214620 (2008-09-01), Heiser
patent: 2008/0249083 (2008-10-01), Schilling
patent: 2008/0286810 (2008-11-01), Demuth
patent: 2009/0018087 (2009-01-01), Schilling
patent: 2009/0068699 (2009-03-01), Schilling
patent: 2009/0149394 (2009-06-01), Schilling
Mayer, et al., Tet. Lett., vol. 46(43), pp. 7393-7396, esp. p. 7395, published Sep. 9, 2005.
Mayer, et al., Tet. Lett., vol. 46(43), pp. 7393-7396, esp. p. 7393.
CAS 296898356.
CAS 499974673.
CAS 896058450.
CAS 896058643.
CAS 896060869.
Barreca ML, et al., Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT, J. Med. Chem., 2005, p. 3433-7, vol. 48(9).
Bateman RC, et al., Evidence for essential histidines in human pituitary glutaminyl cyclase, Biochem., 2001, p. 11246-50, vol. 40(37).
Bockers TM, et al., Glutaminyl-cyclase expression in the bovine/porcine hypothalamus and pituitary, J. Neuroendocrinol., 1995, p. 445-53, vol. 7(6).
Busby WH, et al., An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes, J. Biol. Chem., 1987, p. 8532-6, vol. 262(18).
Consalvo AP, et al., A rapid fluorometric assay for N-terminal glutaminyl cyclase activity using high-performance liquid chromatography, Anal. Biochem., 1998, p. 131-8, vol. 175(1).
Dahl SW, et al., Carica papaya glutamine cyclotransferase belongs to a novel plant enzyme subfamily: cloning and characterization of the recombinant enzyme, Protein Expr. Purif., 2000, p. 27-36, vol. 20(1).
Fischer WH and Spiess J, Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides, PNAS, 1987, p. 3628-31, vol. 84(11).
Messer M, Enzymatic cyclization of L-glutamine and L-glutaminyl peptides, Nature, 1963, p. 1299, vol. 197(4874).
Mironov MA, et al., Ugi reaction with isocyanoindoles, J. Org. Chem., 2004, p. 847-53, vol. 40(6).
Moussaoui A, et al., Revisiting the enzymes stored in the laticifers of Carica papaya in the context of their possible participation in the plant defence mechanism, Cell. Mol. Life Sci., 2001, p. 556-70, vol. 58(4).
Pohl T, et al., Primary structure and functional expression of a glutaminyl cyclase, PNAS, 1991, p. 10059-63, vol. 88(22).
Ugi I, The alpha-addition of immonium ions and anions to isonitriles accompanied by secondary reactions, Agnew. Chem. Internat. Edit., 1962, p. 8-21, vol. 1(1).
Altmstetter Michael
Buchholz Mirko
Heiser Ulrich
Thormann Michael
Treml Andreas
Chung Susannah
Probiodrug (AG)
Sonnenschein Nath & Rosenthal LLP
LandOfFree
Inhibitors of glutaminyl cyclase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of glutaminyl cyclase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of glutaminyl cyclase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4198478